Guadecitabine Extension Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 18, 2018

Primary Completion Date

October 4, 2021

Study Completion Date

October 4, 2021

Conditions
Acute Myeloid LeukemiaMyeloid Dysplastic Syndrome
Interventions
DRUG

Guadecitabine

Guadecitabine

Trial Locations (21)

14263

Roswell Park, Buffalo

19111

Temple University, Philadelphia

27705

Duke Cancer Center, Durham

37203

Center for Blood Cancers, Nashville

43210

Ohio State University, Columbus

44033

Ulsan University Hospital, Ulsan

Unknown

Medizinische Universität Graz, Graz

Rigshospitalet-Copenhagen University Hospital, Copenhagen

Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria, Alessandria

Azienda Ospedaliera Universitaria San Martino, Genova

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

Azienda Ospedaliero Universitaria S. Maria della Misericordia di Udine, Udine

Hospital Universitario 12 de Octubre, Madrid

Mackay Memorial Hospital, Taipei

National Taiwan University Hospital, Taipei

K1H 8L6

The Ottawa Hospital - General, Ottawa

M5G 2M9

Princess Margaret Cancer Center, Toronto

259-1193

Tokai University Hospital, Isehara-shi

602-8026

Japanese Red Cross Kyoto Daini Hospital, Kyoto

849-8501

Saga University Hospital, Saga

03722

Severance Hospital, Yonsei University Health System, Seoul

Sponsors
All Listed Sponsors
lead

Astex Pharmaceuticals, Inc.

INDUSTRY